Display options
Share it on

Cardiovasc Drugs Ther. 1988 Nov;2(4):513-21. doi: 10.1007/BF00051190.

The duration of coronary occlusion influences adrenergic contributions to reperfusion ventricular arrhythmias.

Cardiovascular drugs and therapy

D E Euler, P J Scanlon

Affiliations

  1. Department of Medicine, Loyola University Medical Center, Maywood, Illinois 60153.

PMID: 3154629 DOI: 10.1007/BF00051190

Abstract

To study the role of the adrenergic nervous system in the genesis of nonlethal reperfusion arrhythmias, the proximal left anterior descending coronary artery was occluded for either 1 or 3 hours in 48 open-chest dogs anesthetized with alpha-chloralose. Heart rate was controlled (90 to 110 beats/min) by bilateral vagotomy and continuous right vagal stimulation. Dogs were treated with either saline, timolol (0.1 mg/kg), or prazosin (0.5 mg/kg) 15 minutes prior to reperfusion. Reperfusion after 1 hour of occlusion in saline-treated dogs evoked sustained polymorphic ventricular tachycardia (204 +/- 9 beats/min) that reverted to sinus rhythm by 15 minutes of reperfusion. The maximum rate of ventricular tachycardia was significantly reduced by both prazosin and timolol. Both drugs also caused about a 50% reduction in the total number of ectopic beats in the first 10 minutes of reperfusion. With a 3-hour occlusion, reperfusion in saline-treated dogs caused sustained polymorphic ventricular tachycardia (135 +/- 15 beats/min) which persisted for several hours. Neither timolol nor prazosin significantly altered the ventricular ectopic rate in these dogs. Furthermore, bilateral stellate transection, left stellate stimulation, isoproterenol (0.5 mg/kg), or methoxamine (100 ug/kg) all failed to alter the ventricular ectopic rate in the saline-treated dogs. Ventricular ectopy induced by reperfusion after a 1- or 3-hour occlusion was overdriven in all dogs by rapid atrial pacing. The results suggest that the nature of reperfusion-induced ventricular ectopy is highly dependent upon the preceeding duration of coronary occlusion.(ABSTRACT TRUNCATED AT 250 WORDS)

References

  1. Circ Res. 1987 Sep;61(3):429-35 - PubMed
  2. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50 - PubMed
  3. J Cardiovasc Pharmacol. 1987 Jul;10(1):96-106 - PubMed
  4. J Clin Invest. 1974 Dec;54(6):1496-508 - PubMed
  5. Circulation. 1980 Jan;61(1):175-82 - PubMed
  6. J Electrocardiol. 1985 Jan;18(1):87-96 - PubMed
  7. J Clin Invest. 1980 Jan;65(1):161-71 - PubMed
  8. J Clin Invest. 1981 Apr;67(4):1232-6 - PubMed
  9. J Cardiovasc Pharmacol. 1985;7 Suppl 6:S93-102 - PubMed
  10. Am Heart J. 1981 Apr;101(4):449-56 - PubMed
  11. Eur J Pharmacol. 1977 Sep 15;45(2):127-39 - PubMed
  12. Circulation. 1987 Aug;76(2):404-26 - PubMed
  13. Am J Physiol. 1982 Aug;243(2):H219-25 - PubMed
  14. Circ Res. 1974 Sep;35(3):372-83 - PubMed
  15. J Clin Invest. 1985 May;75(5):1504-9 - PubMed
  16. Circulation. 1985 Jun;71(6):1224-36 - PubMed
  17. J Pharmacol Exp Ther. 1968 Oct;163(2):330-42 - PubMed
  18. Circ Res. 1978 Oct;43(4):512-9 - PubMed
  19. Br J Pharmacol. 1984 Oct;83(2):419-26 - PubMed
  20. Am J Cardiol. 1973 Apr;31(4):474-9 - PubMed
  21. Circulation. 1978 Dec;58(6):1023-35 - PubMed
  22. Circulation. 1981 Feb;63(2):333-40 - PubMed
  23. Cardiovasc Res. 1980 Feb;14(2):116-24 - PubMed
  24. J Cardiovasc Pharmacol. 1980 Jan-Feb;2(1):77-91 - PubMed
  25. J Mol Cell Cardiol. 1984 Dec;16(12):1101-17 - PubMed
  26. Circ Res. 1979 Jun;44(6):833-46 - PubMed
  27. Circ Res. 1987 Jun;60(6):942-51 - PubMed

MeSH terms

Publication Types

LinkOut - more resources